Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 1
2012 2
2013 3
2015 1
2017 3
2018 1
2024 1
2025 1
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of established and off-label ADHD drug therapies for cognitive impairment or attention-deficit hyperactivity disorder symptoms in bipolar disorder: A systematic review by the ISBD Targeting Cognition Task Force.
Miskowiak KW, Obel ZK, Guglielmo R, Bonnin CDM, Bowie CR, Balanzá-Martínez V, Burdick KE, Carvalho AF, Dols A, Douglas K, Gallagher P, Kessing LV, Lafer B, Lewandowski KE, López-Jaramillo C, Martinez-Aran A, McIntyre RS, Porter RJ, Purdon SE, Schaffer A, Stokes PRA, Sumiyoshi T, Torres IJ, Van Rheenen TE, Yatham LN, Young AH, Vieta E, Hasler G. Miskowiak KW, et al. Bipolar Disord. 2024 May;26(3):216-239. doi: 10.1111/bdi.13414. Epub 2024 Mar 3. Bipolar Disord. 2024. PMID: 38433530
RESULTS: Seventeen studies were identified (N = 2136), investigating armodafinil (k = 4, N = 1581), methylphenidate (k = 4, N = 84), bupropion (k = 4, n = 249), clonidine (k = 1, n = 70), lisdexamphetamine (k = 1, n = 25), mixed amphetamine salts (k = 1, n = 30), or modafinil …
RESULTS: Seventeen studies were identified (N = 2136), investigating armodafinil (k = 4, N = 1581), methylphenidate (k = 4, N = 84), bupropi …
Update on treatment for idiopathic hypersomnia.
Evangelista E, Lopez R, Dauvilliers Y. Evangelista E, et al. Expert Opin Investig Drugs. 2018 Feb;27(2):187-192. doi: 10.1080/13543784.2018.1417385. Epub 2018 Jan 3. Expert Opin Investig Drugs. 2018. PMID: 29250981 Review.
Expert opinion: In two recent randomized, double-blind, placebo-controlled trials, modafinil improves EDS in IH. Most of other wakefulness-promoting agents labeled for narcolepsy have similar efficacy in cases series of IH patients. ...
Expert opinion: In two recent randomized, double-blind, placebo-controlled trials, modafinil improves EDS in IH. Most of other wakefu …
The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders.
Mereu M, Bonci A, Newman AH, Tanda G. Mereu M, et al. Psychopharmacology (Berl). 2013 Oct;229(3):415-34. doi: 10.1007/s00213-013-3232-4. Epub 2013 Aug 10. Psychopharmacology (Berl). 2013. PMID: 23934211 Free PMC article. Review.
RATIONALE AND OBJECTIVES: Modafinil (MOD) and its R-enantiomer (R-MOD) are approved medications for narcolepsy and other sleep disorders. ...
RATIONALE AND OBJECTIVES: Modafinil (MOD) and its R-enantiomer (R-MOD) are approved medications for narcolepsy and other sleep disord …
Pharmacological management of narcolepsy with and without cataplexy.
Kallweit U, Bassetti CL. Kallweit U, et al. Expert Opin Pharmacother. 2017 Jun;18(8):809-817. doi: 10.1080/14656566.2017.1323877. Epub 2017 May 17. Expert Opin Pharmacother. 2017. PMID: 28443381 Review.
Expert opinion: Concise evaluation of symptoms and type of narcolepsy, coexisting co-morbidities and patients distinct needs is mandatory in order to identify a suitable, individual pharmacological treatment. First-line options include Modafinil/Armodafinil (for excessive …
Expert opinion: Concise evaluation of symptoms and type of narcolepsy, coexisting co-morbidities and patients distinct needs is mandatory i …
Efficacy of off-label augmentation in unipolar depression: A systematic review of the evidence.
Kleeblatt J, Betzler F, Kilarski LL, Bschor T, Köhler S. Kleeblatt J, et al. Eur Neuropsychopharmacol. 2017 May;27(5):423-441. doi: 10.1016/j.euroneuro.2017.03.003. Epub 2017 Mar 17. Eur Neuropsychopharmacol. 2017. PMID: 28318897
The agents had to be added to an existing antidepressant regime with the aim of achieving an improved clinical response to an ongoing antidepressant treatment (augmentation) or an earlier onset of effect when starting antidepressant and augmentation agent simultaneously (accelera …
The agents had to be added to an existing antidepressant regime with the aim of achieving an improved clinical response to an ongoing antide …
Assessing Condition-Specific Adverse Event Profiles of Modafinil for Labelled and Off-Label Uses: A Systematic Review and Meta-Analysis.
Jung J, Youm J, Kang J, Kim AY, Suh JK, Kang HY. Jung J, et al. Basic Clin Pharmacol Toxicol. 2026 Jan;138(1):e70147. doi: 10.1111/bcpt.70147. Basic Clin Pharmacol Toxicol. 2026. PMID: 41367108 Free PMC article.
Modafinil is a medication used to help people stay awake, especially those with sleep disorders. ...These findings suggest that doctors should consider the patient's specific condition when prescribing modafinil....
Modafinil is a medication used to help people stay awake, especially those with sleep disorders. ...These findings suggest that docto …
Safety profile of modafinil across a range of prescribing indications, including off-label use, in a primary care setting in England: results of a modified prescription-event monitoring study.
Davies M, Wilton L, Shakir S. Davies M, et al. Drug Saf. 2013 Apr;36(4):237-46. doi: 10.1007/s40264-013-0025-y. Drug Saf. 2013. PMID: 23483377
BACKGROUND: Modafinil (Provigil) was marketed in the UK in 1998 to promote wakefulness in the treatment of narcolepsy. ...The review highlighted the degree of off-label usage of modafinil, including patients with multiple sclerosis. OBJECTIVE: The aim of this study …
BACKGROUND: Modafinil (Provigil) was marketed in the UK in 1998 to promote wakefulness in the treatment of narcolepsy. ...The review …
Attitudes Toward Cognitive Enhancer Use Among New Zealand Tertiary Students.
Ram SS, Hussainy S, Henning M, Stewart K, Jensen M, Russell B. Ram SS, et al. Subst Use Misuse. 2017 Sep 19;52(11):1387-1392. doi: 10.1080/10826084.2017.1281313. Epub 2017 Apr 21. Subst Use Misuse. 2017. PMID: 28429997
Commonly used cognitive enhancers (CEs) include methylphenidate, amphetamines, and modafinil. To understand the motivation to use CEs, it is important to look beyond prevalence and explore the extent to which attitudes, beliefs, and intentions predict the decision to use C …
Commonly used cognitive enhancers (CEs) include methylphenidate, amphetamines, and modafinil. To understand the motivation to use CEs …
The prevalence and cost of unapproved uses of top-selling orphan drugs.
Kesselheim AS, Myers JA, Solomon DH, Winkelmayer WC, Levin R, Avorn J. Kesselheim AS, et al. PLoS One. 2012;7(2):e31894. doi: 10.1371/journal.pone.0031894. Epub 2012 Feb 21. PLoS One. 2012. PMID: 22363762 Free PMC article.
RESULTS: We found that prescriptions for lidocaine patch, modafinil, and cinacalcet associated with non-orphan diagnoses rose at substantially higher rates (average monthly increases in number of patients of 14.6, 1.45, and 1.58) than prescriptions associated with their or …
RESULTS: We found that prescriptions for lidocaine patch, modafinil, and cinacalcet associated with non-orphan diagnoses rose at subs …
15 results